Chemed Corporation

CHENYSECIK 19584Healthcare / Healthcare Providers & Servicesfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$691M
+10.6% on Q3 FY2025
Net income
$72M
+11.5% on Q3 FY2025
Free cash flow
$38M
−42.5% on Q3 FY2025
Diluted EPS
$5.45
+22.2% on Q3 FY2025
Revenue, TTM
$2.7B
trailing four quarters
Net margin, TTM
10.6%
net income $282M
Free cash flow, TTM
$295M
$363M less $68M capex
Cash and equivalents
$48M
long-term debt $236M, Sep 30, 2026
Shares, 12-month change
−8.1%
13M shares, Sep 30, 2026
Buybacks, TTM
$525M
7.3% of market value
Dividends, TTM
$34M
0.5% of market value
Market value
$7.1B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Chemed Corporation reported revenue of $691M, +10.6% on Q3 FY2025, and net income of $72M (+11.5%). Operating margin was 14.0%. Free cash flow, operating cash flow less capital expenditures, was $38M ($57M less $19M). Diluted earnings per share were $5.45.

Share price

Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

CHE daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $552.74 · H $552.74 · L $546.55 · C $548.20 · −0.36% on the dayOver the range: +22.91%, Nov 14, 2025 to Nov 13, 2026
$353$409$464$519$574Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5BQ4'22, Revenue: $308MQ4'22, Net income: $62MQ4'22Q1'23, Revenue: $310MQ1'23, Net income: $54MQ1'23Q2'23, Revenue: $321MQ2'23, Net income: $53MQ2'23Q3'23, Revenue: $334MQ3'23, Net income: $75MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $90MQ4'23Q1'24, Revenue: $589MQ1'24, Net income: $65MQ1'24Q2'24, Revenue: $596MQ2'24, Net income: $71MQ2'24Q3'24, Revenue: $606MQ3'24, Net income: $76MQ3'24Q4'24, Revenue: $640MQ4'24, Net income: $90MQ4'24Q1'25, Revenue: $647MQ1'25, Net income: $72MQ1'25Q2'25, Revenue: $619MQ2'25, Net income: $52MQ2'25Q3'25, Revenue: $625MQ3'25, Net income: $64MQ3'25Q4'25, Revenue: $639MQ4'25, Net income: $77MQ4'25Q1'26, Revenue: $658MQ1'26, Net income: $66MQ1'26Q2'26, Revenue: $673MQ2'26, Net income: $68MQ2'26Q3'26, Revenue: $691MQ3'26, Net income: $72MQ3'26$0$500M$1.0B$1.5BQ4'22, Revenue: $308MQ4'22, Net income: $62MQ4'22Q1'23, Revenue: $310MQ1'23, Net income: $54MQ1'23Q2'23, Revenue: $321MQ2'23, Net income: $53MQ2'23Q3'23, Revenue: $334MQ3'23, Net income: $75MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $90MQ4'23Q1'24, Revenue: $589MQ1'24, Net income: $65MQ1'24Q2'24, Revenue: $596MQ2'24, Net income: $71MQ2'24Q3'24, Revenue: $606MQ3'24, Net income: $76MQ3'24Q4'24, Revenue: $640MQ4'24, Net income: $90MQ4'24Q1'25, Revenue: $647MQ1'25, Net income: $72MQ1'25Q2'25, Revenue: $619MQ2'25, Net income: $52MQ2'25Q3'25, Revenue: $625MQ3'25, Net income: $64MQ3'25Q4'25, Revenue: $639MQ4'25, Net income: $77MQ4'25Q1'26, Revenue: $658MQ1'26, Net income: $66MQ1'26Q2'26, Revenue: $673MQ2'26, Net income: $68MQ2'26Q3'26, Revenue: $691MQ3'26, Net income: $72MQ3'26$0$500M$1.0B$1.5BQ4'22, Revenue: $308MQ4'22, Net income: $62MQ1'23, Revenue: $310MQ1'23, Net income: $54MQ1'23Q2'23, Revenue: $321MQ2'23, Net income: $53MQ3'23, Revenue: $334MQ3'23, Net income: $75MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $90MQ1'24, Revenue: $589MQ1'24, Net income: $65MQ1'24Q2'24, Revenue: $596MQ2'24, Net income: $71MQ3'24, Revenue: $606MQ3'24, Net income: $76MQ3'24Q4'24, Revenue: $640MQ4'24, Net income: $90MQ1'25, Revenue: $647MQ1'25, Net income: $72MQ1'25Q2'25, Revenue: $619MQ2'25, Net income: $52MQ3'25, Revenue: $625MQ3'25, Net income: $64MQ3'25Q4'25, Revenue: $639MQ4'25, Net income: $77MQ1'26, Revenue: $658MQ1'26, Net income: $66MQ1'26Q2'26, Revenue: $673MQ2'26, Net income: $68MQ3'26, Revenue: $691MQ3'26, Net income: $72MQ3'26

Net income losses drawn in red.

Free cash flow
$0$50M$100M$150MQ4'22, Free cash flow: $82MQ4'22Q1'23, Free cash flow: $43MQ1'23Q2'23, Free cash flow: $116MQ2'23Q3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $97MQ4'23Q1'24Q2'24Q3'24Q4'24Q1'25, Free cash flow: $19MQ1'25Q2'25, Free cash flow: $123MQ2'25Q3'25, Free cash flow: $66MQ3'25Q4'25, Free cash flow: $117MQ4'25Q1'26, Free cash flow: $71MQ1'26Q2'26, Free cash flow: $69MQ2'26Q3'26, Free cash flow: $38MQ3'26$0$50M$100M$150MQ4'22, Free cash flow: $82MQ4'22Q1'23, Free cash flow: $43MQ1'23Q2'23, Free cash flow: $116MQ2'23Q3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $97MQ4'23Q1'24Q2'24Q3'24Q4'24Q1'25, Free cash flow: $19MQ1'25Q2'25, Free cash flow: $123MQ2'25Q3'25, Free cash flow: $66MQ3'25Q4'25, Free cash flow: $117MQ4'25Q1'26, Free cash flow: $71MQ1'26Q2'26, Free cash flow: $69MQ2'26Q3'26, Free cash flow: $38MQ3'26$0$50M$100M$150MQ4'22, Free cash flow: $82MQ1'23, Free cash flow: $43MQ1'23Q2'23, Free cash flow: $116MQ3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $97MQ1'24Q3'24Q1'25, Free cash flow: $19MQ1'25Q2'25, Free cash flow: $123MQ3'25, Free cash flow: $66MQ3'25Q4'25, Free cash flow: $117MQ1'26, Free cash flow: $71MQ1'26Q2'26, Free cash flow: $69MQ3'26, Free cash flow: $38MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $74MQ4'22, Long-term debt: $93MQ4'22Q1'23, Cash and equivalents: $58MQ1'23, Long-term debt: $16MQ1'23Q2'23, Cash and equivalents: $160MQ2'23Q3'23, Cash and equivalents: $173MQ3'23Q4'23, Cash and equivalents: $264MQ4'23Q1'24, Cash and equivalents: $313MQ1'24Q2'24, Cash and equivalents: $223MQ2'24Q3'24, Cash and equivalents: $238MQ3'24Q4'24, Cash and equivalents: $178MQ4'24Q1'25, Cash and equivalents: $174MQ1'25Q2'25, Cash and equivalents: $250MQ2'25Q3'25, Cash and equivalents: $130MQ3'25Q4'25, Cash and equivalents: $75MQ4'25Q1'26, Cash and equivalents: $17MQ1'26, Long-term debt: $91MQ1'26Q2'26, Cash and equivalents: $40MQ2'26, Long-term debt: $140MQ2'26Q3'26, Cash and equivalents: $48MQ3'26, Long-term debt: $236MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $74MQ4'22, Long-term debt: $93MQ4'22Q1'23, Cash and equivalents: $58MQ1'23, Long-term debt: $16MQ1'23Q2'23, Cash and equivalents: $160MQ2'23Q3'23, Cash and equivalents: $173MQ3'23Q4'23, Cash and equivalents: $264MQ4'23Q1'24, Cash and equivalents: $313MQ1'24Q2'24, Cash and equivalents: $223MQ2'24Q3'24, Cash and equivalents: $238MQ3'24Q4'24, Cash and equivalents: $178MQ4'24Q1'25, Cash and equivalents: $174MQ1'25Q2'25, Cash and equivalents: $250MQ2'25Q3'25, Cash and equivalents: $130MQ3'25Q4'25, Cash and equivalents: $75MQ4'25Q1'26, Cash and equivalents: $17MQ1'26, Long-term debt: $91MQ1'26Q2'26, Cash and equivalents: $40MQ2'26, Long-term debt: $140MQ2'26Q3'26, Cash and equivalents: $48MQ3'26, Long-term debt: $236MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $74MQ4'22, Long-term debt: $93MQ1'23, Cash and equivalents: $58MQ1'23, Long-term debt: $16MQ1'23Q2'23, Cash and equivalents: $160MQ3'23, Cash and equivalents: $173MQ3'23Q4'23, Cash and equivalents: $264MQ1'24, Cash and equivalents: $313MQ1'24Q2'24, Cash and equivalents: $223MQ3'24, Cash and equivalents: $238MQ3'24Q4'24, Cash and equivalents: $178MQ1'25, Cash and equivalents: $174MQ1'25Q2'25, Cash and equivalents: $250MQ3'25, Cash and equivalents: $130MQ3'25Q4'25, Cash and equivalents: $75MQ1'26, Cash and equivalents: $17MQ1'26, Long-term debt: $91MQ1'26Q2'26, Cash and equivalents: $40MQ2'26, Long-term debt: $140MQ3'26, Cash and equivalents: $48MQ3'26, Long-term debt: $236MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Chemed Corporation income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 28, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue691673658639625619647640+10.6%
Cost of revenue458452442417425434431406+7.7%
Gross profit—————————
Research and development—————————
Selling, general and administrative111115114106106100106104+5.4%
Operating income968985101756895114+29.0%
Other income (expense)24559317−74.2%
Pretax income979189105847196120+15.8%
Income tax2524232919192430+29.8%
Net income7268667764527290+11.5%
Diluted EPS ($)5.455.134.84—4.463.574.86—+22.2%
Diluted shares (millions)131314—141515——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Chemed Corporation balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 28, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents48401775130250174178−62.7%
Short-term investments—————————
Total current assets366291274303395491502395−7.5%
Total assets1,7181,5801,5361,5381,6241,7181,7271,669+5.8%
Total current liabilities331320321287292264291286+13.3%
Long-term debt23614091——————
Total debt23614091——————
Total liabilities857749688559547519545550+56.7%
Stockholders’ equity8618318489791,0771,1981,1821,119−20.0%
Shares outstanding (millions)1313131414151515—

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Chemed Corporation cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 31, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed Apr 28, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow5785881348313933165−32.1%
Capital expenditures19161716171613withheld+7.0%
Free cash flow (CFO − capex)3869711176612319—−42.5%
Depreciation and amortization1717171616161616+7.2%
Share repurchases63971901751814333209−65.4%
Dividends paid98889777+6.1%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 27, 2026.

Income statement

Chemed Corporation income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Jul 30, 2010FY2008ended Dec 31, 2008filed Jul 30, 2010
Revenue2,5302,4312,2641,2021,2611,3351,2811,1981,6671,5771,5431,4561,4131,4301,3561,2811,1901,149
Cost of revenue1,7071,5771,4661,3701,3691,3781,3211,2281,1511,1151,0881,0351,0091,033970906835811
Gross profit——————————————————
Research and development——————————————————
Selling, general and administrative417424395359367330306271277244238223216209202202197175
Operating income338366341343343390257244113179184168133156154144126133
Other income (expense)193513(9)999182(1)354126(9)
Pretax income356399350330350396262240117177180163124146141134121115
Income tax919778808277423419687063475755524747
Net income2653022732502693192202069810911099778986827467
Diluted EPS ($)18.3419.8917.9316.5316.8519.4813.3112.235.866.486.335.574.164.624.103.553.242.88
Diluted shares (millions)141515151616171717171718191921232323

Balance sheet

Chemed Corporation balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Jul 30, 2010FY2008ended Dec 31, 2008filed Jul 30, 2010
Cash and equivalents7517826474331636511151514847038501124
Short-term investments——————————————————
Total current assets303395501273230329191160176170151175225198151197198—
Total assets1,5381,6691,6681,4421,3431,4351,268976920880852860894860796830819—
Total current liabilities287286312297302299262192194172171176364157145149136—
Long-term debt———93185—90899110084141184175167159152—
Total debt———98185—908910110991148184175167159152—
Total liabilities559550560643719534542384380356339409445406382368342—
Stockholders’ equity9791,1191,108799623901727591540524513451449453414462477—
Shares outstanding (millions)14151515151616161616171718191921——

Cash flow statement

Chemed Corporation cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Jul 30, 2010FY2008ended Dec 31, 2008filed Jul 30, 2010
Operating cash flow388417330310309489301287162135172——13217486161112
Capital expenditures635057575959535364404444293530262126
Free cash flow (CFO − capex)3253682732532504302482349896127——971456013986
Depreciation and amortization6563615959574539363533312928272626—
Share repurchases432361681155761769315995102591109361144109167
Dividends paid3227242222212019171616141413131286

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$6M
7 sales by 2 insiders; officers and directors $6M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$11M
16 sales by 5 insiders; officers and directors $11M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 13, 2026Lee Spencer Sexecutive vice presidentgift60$0.00—12,871Nov 16, 2026
Nov 11, 2026Lee Spencer Sexecutive vice presidentopen-market sale1,000$547.61$548K12,931Nov 13, 2026
Nov 3, 2026Mcnamara Kevin Jpresident and CEO, Directoropen-market sale2,000$537.90$1M82,220Nov 5, 2026
Nov 2, 2026Lee Spencer Sexecutive vice presidentopen-market sale920$537.17$494K13,931Nov 3, 2026
Sep 30, 2026Lee Spencer Sexecutive vice presidentoption exercise12,099$445.35$5M26,011Oct 1, 2026
Sep 30, 2026Lee Spencer Sexecutive vice presidenttax withholding11,160$508.93$6M14,851Oct 1, 2026
Sep 28, 2026Mcnamara Kevin Jpresident and CEO, Directoropen-market sale2,000$513.45$1M66,418Sep 30, 2026
Sep 28, 2026Hutton Thomas Cvice president, Directoroption exercise4,629$445.35$2M37,110Sep 29, 2026
Sep 28, 2026Hutton Thomas Cvice president, Directortax withholding4,270$506.65$2M32,840Sep 29, 2026
Sep 18, 2026Mcnamara Kevin Jpresident and CEO, Directoropen-market sale2,000$501.40$1M68,418Sep 21, 2026
Aug 21, 2026Lee Spencer Sexecutive vice presidentopen-market sale1,000$541.04$541K13,912Aug 24, 2026
Aug 21, 2026Mcnamara Kevin Jpresident and CEO, Directoropen-market sale2,000$541.16$1M70,418Aug 24, 2026
Aug 10, 2026Judkins Brian CVP and Chief Legal Officeroption exercise6,786$445.35$3M9,222Aug 10, 2026
Aug 10, 2026Judkins Brian CVP and Chief Legal Officertax withholding5,878$548.96$3M3,344Aug 10, 2026
Aug 5, 2026Wherley Joel LCEO - Vitas Healthcareoption exercise2,599$445.35$1M3,451Aug 6, 2026
Aug 5, 2026Wherley Joel LCEO - Vitas Healthcaretax withholding2,270$542.62$1M1,181Aug 6, 2026
Aug 3, 2026Mcnamara Kevin Jpresident and CEO, Directoropen-market sale2,000$539.51$1M70,418Aug 4, 2026
Jul 31, 2026Mcnamara Kevin Jpresident and CEO, Directoroption exercise2,001$445.35$891K92,220Aug 4, 2026
Jul 31, 2026Mcnamara Kevin Jpresident and CEO, Directortax withholding19,802$529.22$10M72,418Aug 4, 2026
Jul 31, 2026Grace Patrick PDirectoropen-market sale190$532.00$101K3,533Aug 3, 2026
Jun 9, 2026Lindell Andrea RDirectoropen-market sale1,347$447.33$603K4,578Jun 10, 2026
May 29, 2026Walsh George J IIIDirectoropen-market sale500$437.83$219K3,209May 29, 2026
May 18, 2026Walsh George J IIIDirectoraward386$440.77$170K3,709May 19, 2026
May 18, 2026Mount John Meredith Jr.Directoraward386$440.77$170K1,316May 19, 2026
May 18, 2026McCarthy Eileen PDirectoraward386$440.77$170K1,241May 19, 2026

Full insider history for Chemed Corporation, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held CHE in their latest 13F filing, through November 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded CHE by quarter.

FundManagerQuarterValueSharesWeightMove
Renaissance TechnologiesPeter BrownQ3 2026$20M38,6800.03%held −1.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CHEMED CORPORATION, CIK 19584 on EDGAR
Extract generated
November 16, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: capex FY2024
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2018, capex FY2024
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total debt: LongTermDebt, noncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/CHE.json